Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.650
-0.260 (-6.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
July 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Preparing For Strategic Growth
July 16, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
July 15, 2024
Via
Investor Brand Network
LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024
July 12, 2024
LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
Via
InvestorPlace
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 09, 2024
Via
ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 08, 2024
Via
ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 18, 2024
Via
ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
June 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
July 09, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
July 09, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
July 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 23, 2024
Via
ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
June 27, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
June 24, 2024
Via
Investor Brand Network
7 A-Rated Penny Stocks to Beat June Gloom
June 24, 2024
Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month.
Via
InvestorPlace
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study
June 18, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
June 17, 2024
Via
Investor Brand Network
7 A-Rated Biotech Stocks Worth Betting on in June
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
June 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
June 05, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
June 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 04, 2024
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!
Via
InvestorPlace
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
June 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
May 30, 2024
Via
Benzinga
7 A-Rated Penny Stocks Work Betting On in H2 2024
May 30, 2024
For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.
Via
InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
May 28, 2024
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
May 28, 2024
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy
May 22, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.